Dr. MoneyBall@Dr_MoneyballWe are a few weeks late on $RGNX initiating their rolling BLA for RGX-202 in 3Q26. Certainly not ideal, but they were just guiding for initiation, so as long as they complete their BLA submission in 1Q, it doesn't really matter when they started it. I believe that the data
Dr. MoneyBall@Dr_MoneyballLots of regulatory uncertainty, but this is the key quote from $RGNX press release today: "In recent discussions with FDA, the agency shared that the use of RGX-202 microdystrophin expression as a surrogate endpoint will be based on the correlation analysis with clinical
